MiniMed Group (NASDAQ:MMED) Research Coverage Started at Bank of America

Bank of America assumed coverage on shares of MiniMed Group (NASDAQ:MMED) in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $27.00 price target on the stock.

Several other analysts have also weighed in on MMED. BTIG Research began coverage on shares of MiniMed Group in a research note on Tuesday. They set a “buy” rating and a $25.00 target price for the company. Wall Street Zen upgraded shares of MiniMed Group to a “hold” rating in a research report on Saturday, March 14th. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, MiniMed Group presently has an average rating of “Moderate Buy” and a consensus price target of $22.45.

MiniMed Group Trading Down 3.2%

MMED stock opened at $14.01 on Tuesday. MiniMed Group has a 12-month low of $13.52 and a 12-month high of $20.48.

Key Headlines Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
• Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
• Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
• Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
• Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
• Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
• Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
• Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
• Neutral Sentiment: Mizuho began coverage on MMED. Article Title
• Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
• Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.